Enterome announced positive Phase I/II results for its oncology vaccine EO2463 as it plans to add another drug candidate to its mimicry drug discovery platform OncoMimics.
The clinical data from the open-label, multicentre Phase I/II trial (NCT04669171) of EO2463, a microbial-derived peptide therapeutic vaccine, as monotherapy, and in combination with Bristol Myers Squibb’s Revlimid (lenalidomide) and Roche’s Rituxan(rituximab), demonstrated strong immune responses associated with early clinical activity for the treatment of patients with indolent Non-Hodgkin’s Lymphoma (iNHL).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Enterome will present the data at the International Conference on Malignant Lymphoma (ICML) taking place from 13-17 June in Lugano, Switzerland.
EO2463 is an off-the-shelf immunotherapy candidate that combines four synthetic microbial-derived peptides that exhibit molecular mimicry with the B lymphocyte-specific lineage markers CD20, CD22, CD37 and CD268 (BAFF receptor), along with the helper peptide (CD4+ epitope) universal cancer peptide 2 (UCP2).
Phase I/II trial data
EO2463 was well tolerated as a monotherapy and when combined with Revlimid and Rituxan. Metabolic marker and tumour size reduction were observed in four out of nine patients after six weeks of EO2463 monotherapy.
According to a press release on 14 June, in six out of eight patients, expansion of specific CD8+ T cells against the mimic peptides and targeted B cell antigens was detected. Even after the addition of rituximab, the immune response was maintained.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataEO2463 reportedly generated on-target immune activation with cytotoxic T cells with the ability to kill malignant HLA-A2 B cell lines in vitro.
Enterome CEO Pierre Belichard said: “This growing set of clinical data gives us confidence in our ability to generate OncoMimics-based immunotherapies targeting unmet needs across a wide range of solid and liquid tumours. Alongside EO2401 and EO2463, we have initiated enrolment for a new clinical study to evaluate EO2040 in patients with colorectal cancer with ctDNA-defined, minimal residual disease. We are also preparing to enter another new OncoMimics candidate, EO4010, for the treatment of metastatic colorectal cancer, into clinical development.”
The French-based company is also developing an EO2401 and Opdivo (nivolumab) combination treatment developed in partnership with Bristol Myers Squibb. It is currently in Phase I/II trials for recurrent glioblastoma (NCT04116658) and adrenocortical carcinoma (NCT04187404).
